292 related articles for article (PubMed ID: 30055635)
1. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
Finney J; Kelsoe G
Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 neutralizing antibodies: understanding nature's pathways.
Mascola JR; Haynes BF
Immunol Rev; 2013 Jul; 254(1):225-44. PubMed ID: 23772623
[TBL] [Abstract][Full Text] [Related]
3. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.
Kobie JJ; Alcena DC; Zheng B; Bryk P; Mattiacio JL; Brewer M; Labranche C; Young FM; Dewhurst S; Montefiori DC; Rosenberg AF; Feng C; Jin X; Keefer MC; Sanz I
PLoS One; 2012; 7(4):e35356. PubMed ID: 22530008
[TBL] [Abstract][Full Text] [Related]
4. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
5. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
6. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.
Verkoczy L; Diaz M
Curr Opin HIV AIDS; 2014 May; 9(3):224-34. PubMed ID: 24714565
[TBL] [Abstract][Full Text] [Related]
7. Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth.
Roskin KM; Jackson KJL; Lee JY; Hoh RA; Joshi SA; Hwang KK; Bonsignori M; Pedroza-Pacheco I; Liao HX; Moody MA; Fire AZ; Borrow P; Haynes BF; Boyd SD
Nat Immunol; 2020 Feb; 21(2):199-209. PubMed ID: 31959979
[TBL] [Abstract][Full Text] [Related]
8. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.
Havenar-Daughton C; Lee JH; Crotty S
Immunol Rev; 2017 Jan; 275(1):49-61. PubMed ID: 28133798
[TBL] [Abstract][Full Text] [Related]
9. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
[TBL] [Abstract][Full Text] [Related]
10. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
Wu X
Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
[TBL] [Abstract][Full Text] [Related]
11. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.
Borrow P; Moody MA
Immunol Rev; 2017 Jan; 275(1):62-78. PubMed ID: 28133804
[TBL] [Abstract][Full Text] [Related]
12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
13. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
14. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
Girard MP; Picot V; Longuet C; Nabel GJ
Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
[TBL] [Abstract][Full Text] [Related]
15. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Kelsoe G; Moody MA; Haynes BF
Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
[TBL] [Abstract][Full Text] [Related]
16. Immunological tolerance as a barrier to protective HIV humoral immunity.
Schroeder KM; Agazio A; Torres RM
Curr Opin Immunol; 2017 Aug; 47():26-34. PubMed ID: 28728075
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
18. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
Medina-Ramírez M; Sanders RW; Klasse PJ
Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
[TBL] [Abstract][Full Text] [Related]
19. Host controls of HIV broadly neutralizing antibody development.
Kelsoe G; Haynes BF
Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
[TBL] [Abstract][Full Text] [Related]
20. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang R; Verkoczy L; Wiehe K; Munir Alam S; Nicely NI; Santra S; Bradley T; Pemble CW; Zhang J; Gao F; Montefiori DC; Bouton-Verville H; Kelsoe G; Larimore K; Greenberg PD; Parks R; Foulger A; Peel JN; Luo K; Lu X; Trama AM; Vandergrift N; Tomaras GD; Kepler TB; Moody MA; Liao HX; Haynes BF
Sci Transl Med; 2016 Apr; 8(336):336ra62. PubMed ID: 27122615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
